Ami Fadia
Stock Analyst at Needham
(4.45)
# 287
Out of 5,163 analysts
353
Total ratings
47.47%
Success rate
25.62%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Reiterates: Buy | $14 | $3.69 | +279.40% | 2 | Mar 9, 2026 | |
| IMRX Immuneering | Reiterates: Buy | $11 | $5.05 | +117.82% | 21 | Mar 9, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Hold | n/a | $21.31 | - | 24 | Mar 6, 2026 | |
| GHRS GH Research | Maintains: Buy | $31 → $32 | $14.95 | +114.05% | 4 | Mar 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $150 → $145 | $94.86 | +52.86% | 28 | Feb 26, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $46 → $44 | $27.61 | +59.36% | 40 | Feb 25, 2026 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $225 | $156.08 | +44.16% | 19 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $187 → $185 | $129.78 | +42.55% | 17 | Feb 12, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $460 → $510 | $293.95 | +73.50% | 17 | Feb 4, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $210 → $235 | $178.55 | +31.62% | 35 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $34.00 | - | 24 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $29 | $20.61 | +40.71% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $27.76 | +58.50% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $3.00 | +166.67% | 10 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $181.55 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.33 | +32.93% | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $4.78 | +506.69% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $15.34 | +1,986.05% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $23.26 | +222.44% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $0.17 | +12,943.48% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $9.30 | +577.42% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $28.57 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $0.88 | +2,395.18% | 4 | Jan 3, 2018 |
AtaiBeckley
Mar 9, 2026
Reiterates: Buy
Price Target: $14
Current: $3.69
Upside: +279.40%
Immuneering
Mar 9, 2026
Reiterates: Buy
Price Target: $11
Current: $5.05
Upside: +117.82%
Day One Biopharmaceuticals
Mar 6, 2026
Downgrades: Hold
Price Target: n/a
Current: $21.31
Upside: -
GH Research
Mar 6, 2026
Maintains: Buy
Price Target: $31 → $32
Current: $14.95
Upside: +114.05%
Revolution Medicines
Feb 26, 2026
Maintains: Buy
Price Target: $150 → $145
Current: $94.86
Upside: +52.86%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Buy
Price Target: $46 → $44
Current: $27.61
Upside: +59.36%
Axsome Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $225
Current: $156.08
Upside: +44.16%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Buy
Price Target: $187 → $185
Current: $129.78
Upside: +42.55%
Praxis Precision Medicines
Feb 4, 2026
Maintains: Buy
Price Target: $460 → $510
Current: $293.95
Upside: +73.50%
Jazz Pharmaceuticals
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $178.55
Upside: +31.62%
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $34.00
Upside: -
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $20.61
Upside: +40.71%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $27.76
Upside: +58.50%
Oct 28, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $3.00
Upside: +166.67%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $181.55
Upside: -
May 28, 2025
Initiates: Buy
Price Target: $35
Current: $26.33
Upside: +32.93%
May 2, 2025
Reiterates: Buy
Price Target: $29
Current: $4.78
Upside: +506.69%
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $15.34
Upside: +1,986.05%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $23.26
Upside: +222.44%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $0.17
Upside: +12,943.48%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $9.30
Upside: +577.42%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $28.57
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $0.88
Upside: +2,395.18%